Tscan Therapeutics, Inc. · NASDAQ:TCRX
Tscan Therapeutics — Investor Presentation (September 2026)
21 slides from Tscan Therapeutics's investor presentation, Sep 2, 2026
Slide 1: Corporate Presentation September 2026
Corporate Presentation September 2026 Exhibit 99.2
Slide 2: Disclaimers and forward-looking statements
Disclaimers and forward-looking statements This presentation and the accompanying discussion contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, express or implied statements regarding TScan Therapeutics, Inc.'
Slide 3: Strategic prioritization to focus on in vivo cell therapy for solid tumor indications
Strategic prioritization to focus on in vivo cell therapy for solid tumor indications In vivo lentivirus platform developed Two product candidates advanced to IND-enabling Preclinical data and regulatory updates – Q1 2027 File first IND – Q3 2027 Launch P1 clinical trial – Q4 2027 SOLID TUMORS HEME
Slide 4: Focus on in vivo-engineered TCR-T cell therapies for solid tumors
Focus on in vivo-engineered TCR-T cell therapies for solid tumors Indications Program (Targets) SOLID TUMORS Autoimmunity IND-enabling Phase 1 Target-directed therapeutics In vivo-engineered TCR-T cell therapies Ankylosing spondylitis and other HLA-B*27-associated diseases Discovery TSC-303-A02 (PRA
Slide 5: Solid Tumors
Solid Tumors Developing in vivo-engineered TCR-T cell therapy for solid tumor indications
Slide 6: High mortality persists in solid tumor indications despite approved therapies
THE UNMET NEED High mortality persists in solid tumor indications despite approved therapies 550,000 deaths from solid tumor indications are expected in the U.S. in 2026 125,000 deaths occur annually from non-small cell lung cancer despite ~50 approved therapies TARGETABLE BIOLOGY TScan's TCR-T ther
Slide 7: Lentiviral-based in vivo engineering addresses key challenges of autologous TCR-T
Lentivirus Lentiviral-based in vivo engineering technology addresses the key challenges of autologous TCR-T cell therapy In vivo engineering solves the key challenges of autologous TCR-T No patient-specific manufacturing, eliminating out-of-spec issues and significantly reducing cost of goods No vei
Slide 8: Early data from in vivo CAR-T programs in heme malignancies show remarkable response rates
Early data from in vivo CAR-T programs in heme malignancies show remarkable response rates PROOF-OF-CONCEPT IN HEME MALIGNANCY SPACE In vivo-engineered CAR-T programs are showing deep responses and durable T-cell persistence 100% MRD-negative responses at 1 month (n=18) 100% MRD-negative responses a
Slide 9: In vivo-engineered TCR-T provide a promising way to address solid tumor indications
In vivo-engineered TCR-T provide a promising way to address solid tumor indications Tumor cell T cell HLA class I (e.g., A*02:01) Target antigen (e.g., PRAME) CD8a/b TCR PRAME is expressed at high levels in cutaneous melanoma* *Data on file from TScan screening study in solid tumors (NCT05812027) TC
Slide 10: T-cell targeting antibodies direct the virus to cytotoxic and helper T-cells
T-cell targeting antibodies direct the virus to cytotoxic and helper T-cells Antibodies simultaneously target and activate T-cells, enabling rapid expansion in vivo Non-targeting fusogen mediates entry exclusively to T-cells TScan’s third generation lentiviral vector enables in vivo generation of TC
Slide 11: Solid tumor program on track to initiate Phase 1 development in Q4 2027
Solid tumor program on track to initiate Phase 1 development in Q4 2027 UPCOMING MILESTONES Q2 2026 INTERACT meeting with U.S. FDA Q1 2027 Present preclinical data Provide regulatory update Q3 2027 File first IND Q3 2026 Lead candidates identified Advanced to IND-enabling activities Q2 2027 Initiate
Slide 12: Heme Malignancies
Heme Malignancies Targeting residual disease to prevent relapse in patients undergoing allogeneic HCT
Slide 13: TSC-101 is designed to target residual disease and prevent relapse in HCT patients
TSC-101 is designed to target residual disease and prevent relapse in patients undergoing hematopoietic cell transplantation * Infusion 1 & 2 site of care (inpatient vs outpatient) determined by administering physician. Infusion 1 may be given upon engraftment and between days 14-35 post transplant,
Slide 14: Patients generally well balanced across TSC-101 and control arms
Patients generally well balanced across TSC-101 and control arms although Cohort C included a higher percentage of high-risk patients TSC-101 Cohort A TSC-101 Cohort C Control Evaluable Subjects* 19 14 19 Age, Median years (Range) 65 (52-74) 68 (28-79) 66 (23-77) Sex, Male 13 (68%) 9 (64%) 9 (47%) U
Slide 15: Pre-transplant MRD is associated with a very high risk of relapse in AML patients
Pre-transplant MRD is associated with a very high risk of relapse in AML patients Retrospective analysis of 392 patients with AML(1) All patients received NMA- or RIC-HCT 75% of patients had intermediate or high-risk genetics Cumulative incidence of relapse was 50-60% for patients that were MRD-posi
Slide 16: All Cohort C patients were at high risk of relapse
All 14 Cohort C patients were at high risk of relapse: 12 were MRD-positive and remaining 2 were p53m Disease Time post-HCT (days) MRD-positive MRD-negative MRD pending TSC-101 infusion Pre-HCT MRD Dose level HCT DL3AMLMMUD DL4MDSHaplo DL4AMLHaplo DL4ALL-p53mHaplo DL4MDS-p53mMMUD DL4AMLHaplo DL4MDSM
Slide 17: All patients in Cohort C had complete donor chimerism at last assessment
04-022 07-012 13-014 14-003 25-016 13-016 14-004 13-018 13-021 07-013 27-004 16-003 13-017 13-019 1 2 3 4 5 6 7 8 9 10 11 12 13 14 Despite being at high risk of relapse, all patients in Cohort C had complete donor chimerism at their last assessment, including both patients who relapsed DL4 DL4 DL3 D
Slide 18: Donor chimerism results including both patients who relapsed
Despite being at high risk of relapse, all patients in Cohort C had complete donor chimerism at their last assessment, including both patients who relapsed % recipient chimerism % recipient chimerism Donor chimerism results using investigational next-generation sequencing assay (Alloheme) with data
Slide 19: No dose-limiting toxicities were observed across either treatment cohort
No dose-limiting toxicities were observed across either treatment cohort Treatment-emergent acute GvHD occurred in most patients, mainly Grade I–II 74% Cohort A, 36% Cohort C, 63% Control; only 1 Grade III event each in Cohort A and Control, and no Grade IV events No moderate or severe chronic GvHD
Slide 20: Upcoming milestones
Upcoming milestones Solid Tumor Program 2026 H1 2027 Initiated IND-enabling studies for 2 in vivo TCR-T candidates H2 2027 File first IND for in vivo-engineered TCR-T (Q3 2027) Heme Program Report updated data from Cohort C of Phase 1 for TSC-101 (Q4 2026) Report data on all patients treated with co
Slide 21: Thank You
THANK YOU
TScan Therapeutics — Investor Presentation (September 2026) on 6ix